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Abstract
Costs incurred during care-seeking for chronic respiratory disease are a major problem with severe consequences
for socio-economic status and health outcomes. Most of the published evidence to date relates to tuberculosis (TB)
and there is a lack of information for the major non-communicable chronic respiratory diseases: asthma and
chronic obstructive pulmonary disease (COPD). International policy is recognising the need to address this problem
and measure progress towards eliminating catastrophic care-seeking costs (see the post-2015 TB strategy). Current
tools for measuring, defining, and understanding the full consequences of catastrophic care-seeking costs are
inadequate. We propose two areas of work which are urgently needed to prepare health systems and countries for
the burden of chronic lung disease that will fall on poor populations in the coming 10-20 years:
a) Rapid scale up of the number and scope of studies of patient costs associated with chronic non-communicable
respiratory disease.
b) Work towards deeper understanding and effective measurement of catastrophic care-seeking costs.
This will produce a range of indicators, such as dissaving, which can more effectively inform health policy decision-
making for lung health. These will also be useful for other health problems. We argue that reduction in care-
seeking costs will be a key monitoring indicator for improvements in lung health in particular, and health in
general, in the coming 10 to 20 years.
Introduction
The term ‘catastrophic costs’ is commonly used to refer
to healthcare costs that place excessive burdens on
patient households. Health expenditure is said to be cata-
strophic if it ‘threatens a household’s ability to meet its
subsistence needs [1]. This is a useful concept in helping
to set a benchmark within the overall health systems
strengthening goal of social and financial risk protection.
Health systems should function in such a way as to mini-
mise the extent to which patients and their households
or families have to use their own private resources (out-
of-pocket expenditure) to finance health care seeking
activities. This is not only a matter of providing Universal
Health Coverage to reduce direct medical costs (such as
consultation fees, costs of laboratory tests and imaging,
and drugs), but also a matter of paying attention to the
other building blocks of health systems so that health ser-
vices are provided in ways that enable patients to follow
simplified care-seeking pathways. Simplified care-seeking
pathways require fewer health facility visits and their
attendant direct non-medical costs (such as food and
transport) and indirect costs (lost income).
While useful as a concept, catastrophic costs are pro-
blematic in terms of precise definition, understanding
and accurate measurement. Minimisation of catastrophic
costs would be an attractive indicator of effective health
system function, but patient costs are not measured sys-
tematically on a wide scale in routine health service deliv-
ery, and are difficult to bench mark against either
individual or household income. This is an issue for all
health service delivery, and particularly for chronic dis-
ease management which requires long term and repeat
engagement with health services. Chronic diseases are
predicted to be an increasing problem over the coming
10-20 years in developing countries. Within this large
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category of disease, chronic respiratory disease will be a
particular problem amongst poor populations (see
CAHRD Papers LH Biomass, Cough). In this paper,
therefore, we assess the current state of knowledge about
patient costs and catastrophic costs in chronic respiratory
disease. We present ideas on how this knowledge informs
plans for the essential future work that is required to
develop approaches to the measurement, understanding,
and use of catastrophic costs in evaluating effectiveness
of lung health interventions in particular and health sys-
tems in general.
Evidence for the magnitude of the problem of
care-seeking costs in chronic lung disease
Over the past 20 years there have been a number of stu-
dies from across the globe highlighting that TB patients
incur substantial costs during care seeking in low and
middle income countries. These studies have recently
been brought together into a single systematic review(1).
There have also been two previous systematic reviews of
relevant studies from Africa [3,4]. In the most recent
review(1)], 49 studies met the inclusion criteria and
costs were stratified into direct medical costs (consulta-
tions, tests, medicine, hospitalisation, etc) direct non-
medical costs (transport & food during health care visits
etc) and indirect costs (lost income). Costs were also
reported as a percentage of annual income expressed in
a number of different ways. Key results are summarised
in Table 1.
Depending on the type of costs reported, costs varied
from a small fraction of mean monthly income for aver-
age annual income earners to over 10 times the annual
income that the average person in the income-poorest
20% of the population earns. It is striking that these
impoverishing expenditures have been recorded even in
health systems which provide services free at the point
of delivery (ie no user-fees) [5]. This indicates that even
when a health system provides universal health cover-
age, care-seeking costs can be catastrophic.
In the systematic review the cost components were
extracted separately for pre- and post-TB treatment per-
iods and, in broad terms, 50% of total costs were
incurred during care-seeking before diagnosis as illu-
strated in Figure 1.
By contrast with this wealth of knowledge for TB,
there is a marked lack of published studies from low
and middle income countries on the patient costs asso-
ciated with the major non-communicable lung diseases
– asthma and chronic obstructive airways disease
(COPD). Only one study has documented the cost of
inhaled corticosteroids for asthma(2)]. It surveyed the
prices and policies for components of asthma treatment
in 1998 in Algeria, Burkina Faso, Ivory Coast, Guinea,
Mali, Syria, Turkey and Vietnam and documented that
in all but two countries, the cost of one year of drugs
for treatment of a moderate, persistent asthma case
exceeded the monthly salary of a nurse in that country.
We were unable to find published information on costs
incurred in care-seeking by asthma patients. One study
from China on COPD patients includes some data on
patient costs and documents that the mean yearly direct
economic burden of one COPD patient accounted for
an average of one third of family income(3)]. One mod-
eling study of the cost-effectiveness of asthma and
COPD interventions in Sub-Saharan Africa and South
East Asia ranks low dose inhaled corticosteroids for
mild persistent asthma as the most cost-effective of the
interventions studied [8]. However the source for the
patient costs used in the model is not clear.
Evidence of the impact of catastrophic care-
seeking costs on socio-economic status and
health outcomes
In the TB literature to date, various possible definitions
of “catastrophic” costs have been proposed: “>10% of
monthly household income”(4)], “>10% of annual house-
hold income(5)] and [11], >40% of non-subsistence
household income [12] and [13]. WHO suggests that
“catastrophic health expenditure” should be defined as
“direct healthcare expenditures corresponding to >40%
of annual discretionary income (income after basic
needs, such as food and housing [14]. Whichever defini-
tion is adopted, catastrophic health expenditures lead to
reduced food consumption, taking children out of
Table 1. Patient costs as a percentage of annual income (average of mean) from [2]
Studies n Direct costs % Lost income % Total cost %
Individual
Reported income 22 21 37 58
Annual Wage2 35 9 21 30
Wage of lowest 20%3 34 25 64 89
Reported household income 7 16 22 39
2 Computed from “gross average nominal monthly wage in the International Labour Organisation’s global wage database http://www.ilo.org/travil/info/db/lang–
en/index.htm
3 World Bank. Income Share Held by Lowest 20% in the World Bank Database http://data.workdbank.org/indicator/SI.DST.FRST.20/countries
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school, taking out loans, and selling assets. Each of these
coping mechanisms leads to further impoverishment of
individuals and households and the establishment of a
vicious and progressive negative interaction between TB
and poverty.
Pre-diagnostic costs, which are usually the costs
incurred in care-seeking for patients who have chronic
cough, (not just TB) are also obstacles which are diffi-
cult for poorer patients to overcome. In this way, these
costs also contribute to the problem of drop-out
between the start of care-seeking, the initiation of TB
treatment and successful cure. While factors, including
patient costs, which affect drop-out after the start of TB
treatment have received much attention(6), the problem
of drop-out between the start of care-seeking and the
start of TB treatment has been less studied. This has
partly been rectified by a recent systematic review which
has quantified the drop-out between diagnosis and the
start of treatment(7) to be around 15%. The problem of
drop-out between the start of care-seeking and diagnosis
is more difficult to study because
a) there is considerable difficulty in defining and cap-
turing the start date of care seeking or onset of symp-
toms, and
b) care seeking costs at this stage are incurred for all
chronic cough patients even though fewer than 20% will
end up with a diagnosis of TB.
It is likely that drop out for this stage is at least as
large as drop-out for the stage between diagnosis and
the start of treatment. For both stages, drop-out is likely
to be exacerbated when patients face substantial care-
seeking costs and will lead to poor health outcomes for
all patients with chronic respiratory disease.
There are also wider consequences than the direct
effects on patients themselves. For TB patients there is
the added public health consequence of leaving patients
untreated and acting as sources of on-going transmis-
sion of infection. For asthma patients and their families
there are the costs of emergency room treatment for
acute exacerbations that could have been averted by
coherent diagnostic and treatment services (see CAHRD
Paper LH Cough).
Recognition of the importance of catastrophic
costs in international policy: the post 2015
STOP-TB Strategy
Prior to 2015, none of the strategic TB control frame-
works (DOTS, the Stop TB Strategy and the Global Plan
to Stop TB 2006–2015) included a specific target on
poverty. This has now changed. On 19th May 2014, the
World Health Assembly endorsed a strategy which
includes a target that “no families will face catastrophic
costs due to TB by 2020”. Achievement of this target is
to be maintained through to 2035 (see Table 2) &http://
www.who.int/tb/post2015_TBstrategy.pdf?ua=1
The post-2015 TB strategy contains a strong focus on
measures to promote the attainment of this target
within the TB community (the development of patient-
centred care), within the health sector (progress towards
universal health coverage) and beyond the health sector
(social protection).
For TB at least, meaningful, evidence-based indicators
of catastrophic costs which can be used at scale will be
needed. Given predictions about the rise in non-
communicable respiratory disease, such indicators are
likely to become increasingly important for all patients
with chronic respiratory disease. Although patient ques-
tionnaires (see below) to measure these indicators have
been developed and used in TB, there is little experience
of their use for other chronic respiratory disease and they
are far from being fit for purpose.
Problems with defining catastrophic costs and
developing practical indicators
In practice, catastrophic costs are commonly defined as
a threshold percentage of income or usual expenditure.
There is, however, considerable debate as to the appro-
priate threshold to use to define costs as catastrophic
(see above). There are problems defining and measur-
ing discretional expenditure and the threshold for
Figure 1 Breakdown of direct and indirect costs before and during
treatment (8 studies) (1)
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catastrophic total cost (including indirect costs) has
not yet been established.
Calculating patient costs involves completing lengthy
and complex patient cost questionnaires. Early iterations
of such questionnaires [8,9] were further developed by
the TB & Poverty Subgroup of The STOP-TB Partner-
ship into a patient costing tool http://www.stoptb.org/
wg/dots_expansion/tbandpoverty/spotlight.asp). Even
though considerable efforts were made to make this tool
as user-friendly as possible, experience of its use in a
number of settings [10] and [11] indicates that it is too
cumbersome for routine use in monitoring and evalua-
tion. In addition it is subject to recall bias.
There are well known methodological challenges in the
identification and measurement of indirect costs. Similarly,
accurately quantifying income in the most disadvantaged
patient groups is challenging. Such patients will often not
receive a regular cash income, but rely on a range of activ-
ities generating cash and in-kind income that is irregular
and subject to seasonal fluctuations. For this reason, aca-
demic research often relies on indirect measurement of
income via socioeconomic indicators. This also involves
complex questionnaire-based analyses of, for example,
asset ownership. Estimation of catastrophic costs in terms
of cost/income ratios is therefore a significant difficulty in
research projects, and may be unfeasible in routine moni-
toring of policy and practice.
Implications of work on care-seeking costs in TB
for chronic respiratory disease
To date the literature on care-seeking costs has been
based on research amongst patients who have achieved a
diagnosis of TB and has involved asking them to recall
their experiences leading up to diagnosis and through
treatment. There are several problems with this situation.
First there is the problem of recall bias (see above).
Second it means that there is a dearth of information
about care-seeking costs amongst TB patients who never
achieve a diagnosis. For most TB patients, care seeking
starts with the development of a persistent, chronic
cough. This is a common symptom affecting 5-10% of
the adult population in developing countries [12].
Although primary health care services are alerted to the
importance of testing for TB in patients with chronic
cough, we know that even in high burden TB countries
fewer than 20% of such patients will have TB [19]. Infor-
mation on the nature of disease amongst the remaining
80% of patients is scarce. There is, however, increasing
information suggesting that not all of this disease burden
is due to infectious agents; non-communicable airways
disease (asthma, bronchiectasis and chronic obstructive
pulmonary disease) is of increasing importance. There
are indications that patients with chronic cough who are
not diagnosed with TB have poor outcomes [13] suggest-
ing that care provision for them is inadequate. In many
settings, HIV co-infection will also influence care-seeking
behaviour and costs both for those with TB and those
without. It is clear that the burden of non-communicable
respiratory disease will rise inexorably in developing
countries over the next 10-20 years and risk factors for
these, such as exposure to indoor air pollution (see
CAHRD Paper LH Biomass) and tobacco smoke are also
risk factors for TB. Finally, the chronicity and disability
that are associated with COPD and asthma are additional
factors which are likely to escalate the burden of patient
costs.
Overall, therefore, there is a clear need to broaden
investigation of care-seeking costs from patients with
TB to include patients with undifferentiated chronic
cough and to work from there towards understanding
and reducing these costs for non-TB causes of chronic
cough.
A way forward
We propose two initial areas of work which are urgently
needed to prepare health systems and countries for the
burden of chronic lung disease that will fall on poor
populations in the coming 10-20 years:
A. Rapid scale up of the number and scale of studies of
patient costs associated with chronic non-communicable
respiratory disease.
The first step should be the conduct of a systematic
review of the existing literature in this field. This would
serve to better understand the gaps in the knowledge
Table 2. Key global indicators, milestones and targets for the post-2015 tuberculosis strategy
Indicators with baseline values for 2015 Milestones Targets
2020 2025 2030 2035
Percentage reduction in deaths due to tuberculosis
(projected 2015 baseline: 1.3 million deaths)
35% 75% 90% 95%
Percentage and absolute reduction in tuberculosis incidence rate









Percentage of affected families facing catastrophic costs due to
tuberculosis1
(projected 2015 baseline: not yet available)
Zero Zero Zero Zero
1The fact that there is no baseline from which to work is indicative of the problems faced in measurement of this target.
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about these costs and the tools that have been used to
measure them. Following the systematic review, there
should be a series of studies which could use modifica-
tions of the data collection tools that have been devel-
oped for TB, where the modifications are informed by
the findings of the systematic review.
B. Work towards deeper understanding and effective
measurement of catastrophic care-seeking costs.
We suggest an alternative approach to the question-
naire-based data collection and analysis approaches
which have been used to date and described above. This
new approach focuses on the sacrifices households make
to finance healthcare expenditure. These may include
reduction in consumption, withdrawing children from
school, and so on. A common coping strategy is to draw
on the financial resources available to the household for
consumption smoothing, either by disposing of assets or
taking out loans. We refer to this strategy as ‘dissaving’,
as it involves reducing the financial resources available to
protect the household from further shocks. It is effec-
tively the opposite of ‘saving’, which strengths the finan-
cial resources of the household (see Figure 2). Dissaving
can easily and quickly be measured by surveys, and is
likely to be correlated with excessive costs. A survey of
households in 40 developing countries found that 1 in 4
borrowed money or sold assets to fund healthcare costs
[21], and that the poorest households were most likely to
dissave. However, there is limited research on the exact
relationship between dissaving and catastrophic health-
care expenditure, the importance of the type of asset
being sold or the source of loan finance, and the impact
of dissaving on household wellbeing.
A theoretical model of household decision-making
when seeking health care under financial pressure would
be a useful guide for the design, evaluation and selection
of both social protection and health interventions for
patients with chronic respiratory disease. A number of
decision-making models have been developed within the
economics literature, based on Grossman’s work on
health capital production [24] Models have been devel-
oped that treat households as single entities, as multiple
individuals making cooperative decision to jointly pro-
duce household health and as multiple decision-makers
with independent (and possibly conflicting) goals [14,15]
While such models have been widely used in high-
income country settings to model choices such as smok-
ing, vaccination take-up, and childhood obesity, research
on their use and effectiveness in low and middle income
settings is limited. The assumption of rational decision-
making which underpins these models may turn out to
be unrealistic and over-simplistic. Theoretical decision
models drawing on other social sciences, that incorpo-
rate concepts such as behavioural norms, gender analy-
sis and cultural influence, may provide an approach
more consistent with observed behaviour.
We propose a programme of empirical research to col-
lect evidence on the impact on households of costs asso-
ciated with seeking health care for chronic respiratory
disease, the actions taken by household members in
response to this financial stress, the consequences of
those actions for household health and well-being, and
the decision-making process behind household actions.
The aims of this research are two-fold. Firstly, we aim to
identify and validate indicators (such as dissaving) for
catastrophic health care expenditure in its underlying
sense – that of resulting in long-term significant impov-
erishment of those affected. These indicators should be
simple enough for use in routine monitoring and evalua-
tion, and validated by our research as indicative of severe
and lasting financial distress. Secondly, we aim to evalu-
ate and refine alternative theories of household decision-
making to identify models consist with actual behaviour
in low-income settings. We anticipate that validated the-
oretical models will be extremely useful for policy-makers
in the selection and design of interventions around social
protection, poverty reduction, and universal health care
implementation.
The proposed programme of research will draw on a
range of qualitative and quantitative methods to provide
evidence that is robust and captures the complex deci-
sion-making context faced by poor households under
health-related financial pressures. It will be carried out in
low and middle income countries and integrated with
intervention studies aimed at reducing catastrophic costs
and improving access to health services. It will draw on
relevant applied and methodological expertise across
LSTM and the University of Warwick, as well as the net-
work of in-country research organisations where links
have already been established. In addition, capacity to
undertake this work and use it to influence delivery and
Figure 2 Dissaving as an economic concept Adapted from [22].
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policy will need to be strengthened in existing and new
in-country collaborating organisations.
Conclusions
Costs incurred during care-seeking for chronic respira-
tory disease are a major problem with severe conse-
quences for socio-economic status and health outcomes.
Most of the published evidence to date relates to tuber-
culosis (TB) and there is a lack of information for the
major non-communicable chronic respiratory diseases,
asthma and chronic obstructive pulmonary disease
(COPD). Current tools for measuring, defining, and
understanding the full consequences of catastrophic
care-seeking costs are inadequate. Two areas of work are
urgently needed to prepare health systems and countries
for the burden of chronic lung disease that will fall on
poor populations in the coming 10-20 years:
a) Rapid scale up of the number and scope of studies of
patient costs associated with chronic non-communicable
respiratory disease.
b) Work towards deeper understanding and effective
measurement of catastrophic care-seeking costs.
This will produce a range of indicators, such as dissav-
ing, which can more effectively inform health policy
decision-making for lung health. They may also be use-
ful for other health problems. Reduction in care-seeking
costs will be a key monitoring indicator for improve-
ments in lung health in particular, and health in general,
in the coming 10 to 20 years.
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